Answers are grounded in this paper and cite their sources.
Incretin-based therapies have transformed obesity treatment, but evidence in older adults remains limited. Available analyses indicate that weight-loss efficacy is broadly preserved after the age of 65, and no consistent age-specific safety signal has emerged. However, adults aged ≥ 75 years, particularly those with frailty, sarcopenia, malnutrition, or functional impairment, remain underrepresented. Gastrointestinal adverse events may have greater clinical consequences in older adults as reduced intake, dehydration, and medication interactions may compromise physiological reserve. Weight loss also induces loss of lean tissue, although current data do not establish that this routinely translates into sarcopenia or functional decline. Clinical care should focus on net benefit rather than weight reduction alone, incorporating nutritional status, muscle strength, physical function, multimorbidity and polypharmacy. Prospective studies enriched for the oldest and frailest adults are needed to define optimal treatment intensity, monitoring, and functional outcomes.
No takes yet. Share an insight, caveat, or question.
Koceva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: